Ekzifin gel naruzhn.prim-I 1% 15g tube

$7.89

Ekzifin gel naruzhn.prim-I 1% 15g tube

Quantity:

SKU: 908234164 Categories: , , Tag:

Description

Composition
Active substance:
10.0 mg terbinafine.
Excipients:
isopropyl myristate, butyl hydroxy toluene, benzyl alcohol, sorbitan laurate, polysorbate 20, carbomer 974P, sodium hydroxide, disodium edetate, ethanol, purified water.
Description:
Homogeneous gel white to off-white color with no visible foreign particles.
Product form:
Gel for external application of 1%.
15 g in the aluminum tube with a protective membrane made of aluminum and a cover of high density polyethylene, provided with lip for perforating the membrane. Tube with instructions for use placed into cardboard pack.
Contraindications
Increased sensitivity to terbinafine or any of the excipients of the drug, lactation, infancy (up to 18 years).
Carefully
Caution must be exercised when applying the drug to damaged skin, because the alcohol contained in the product, may cause irritation.
Dosage
1 %
Indications
Treatment and prevention of fungal infections of the skin, including:
– mycosis stop ( “fungus” foot);
– jock itch (tinea cruris);
– fungal lesions of the smooth skin of the body (tinea corporis), caused by dermatophytes such as:
– Trichophyton (including T. rubrum, T. mentagrophytes, T. verrucosum, T. violaceum);
– Microsporum canis;
– Epidermophyton floccosum.
Pityriasis versicolor (Pityriasis versicolor), caused by Pityrosporum orbiculare (also known as Malassezia furfur).
If necessary, please consult your physician before using the drug.
Interaction with other drugs
Interaction with terbinafine external application has not been studied.
Overdose
Cases of overdose of terbinafine for external use have been reported. In applying the drug in accordance with the instruction overdose unlikely. If accidentally receiving more inwardly gel can expect development of the same adverse reactions, as when an overdose of terbinafine in the dosage form of a tablet (headache, nausea, epigastric pain and dizziness).
Treatment: activated charcoal, symptomatic supportive therapy.
pharmachologic effect
Pharmacological group:
antifungal agent.
Pharmacodynamics:
Antifungal agent for external application, with a broad spectrum of antifungal activity. At low concentrations of terbinafine has fungicidal activity against dermatophytes (Trichophyton rubrum, T. mentagrophytes, T. verrucosum, T. violaceum, T. tonsurans, Microsporum canis, Epidermophyton floccosum), yeasts (mainly C. albicans) and certain dimorphic fungi ( Pityrosporum orbiculare). Activity against yeast fungi, depending on their type, may be a fungicidal or fungistatic.
Terbinafine specifically alters the early stage of the biosynthesis of sterols, occurring in fungi. This leads to a deficiency of ergosterol and to an intracellular accumulation of squalene, which causes death of fungal cells. Action terbinafine accomplished by inhibition of the enzyme squalene epoxidase located on the cell membrane of the fungus.
Terbinafine has no effect on cytochrome P450 system in humans and, accordingly, the metabolism of hormones or other drugs.
Pharmacokinetics:
When applied topically absorption – less than 5% has little systemic effect.
Pregnancy and breast-feeding
In studies conducted on animals teratogenic properties of terbinafine have been identified. To date, no reports of any malformations in the application of terbinafine. However, as clinical experience with terbinafine gel in pregnant women is very limited, its application is possible if the expected benefit to the mother outweighs the potential risk to the fetus.
Terbinafine is excreted in breast milk, so the drug should not be administered to nursing mothers. Avoid contact with the baby’s skin surface treated with a drug, including breast skin surface.
Conditions of supply of pharmacies
Without a prescription.
side effects
The classification of the frequency of occurrence of adverse reactions: very often (> 1/10 destinations), often (1/10 – 1/100 destinations); infrequently (1/100 – 1/1000 destinations); rare (1/1000 – 1/10 000 destinations), very rarely (> 1/10 000), the frequency is unknown (frequency can not be estimated from the available data).
Violations by the immune system
The frequency is not known – hypersensitivity reaction *.
Violations by the organ of vision
Rarely – eye irritation.
Violations of the skin and subcutaneous tissue
Often – skin peeling, itching; infrequently – damage to the skin, crusting, disorders of the skin, pigmentation disorders, erythema, burning sensation of the skin; rarely – a feeling of dry skin, contact dermatitis, eczema; the frequency is unknown – rash *.
General disorders and the site of application
Uncommon: pain, application site irritation at the site of application.
Rarely – worsening symptoms.
* Based on post-marketing experience of the application.
If any of these instructions side effects are compounded, or if you notice any other side effects not mentioned in the instructions, tell your doctor.
special instructions
Ekzifin® intended for external use only. Avoid getting product in eyes, as it may cause irritation. In case of accidental contact with the drug in their eyes, immediately rinse with running water, and in the case of persistent phenomena of irritation consult a doctor.
The preparation contains butylhydroxytoluene, which might cause local allergic reactions (dermatitis) in areas of application, as well as irritation of eyes and mucous membranes.
Caution must be exercised when using the drug Ekzifin®, as part of the alcohol gel can cause skin irritation.
Carefully read the manual before you start using the product. Keep these instructions, it may be needed again. If you have any questions, consult your doctor. Medicines that you are being treated, meant to you personally, and should not be transferred to other persons as it may harm them even if you have the same symptoms that you have.
Effect on driving ability
Does not affect.
Storage conditions
At temperatures above 25 ° C.
Keep out of the reach of children!
Dosing and Administration
Outwardly.
Adults and children over 18 years. Terbinafine gel used 1 time per day for all indications.
The duration of treatment and the multiplicity of the drug:
– ringworm of the body, legs: 1 week 1 time per day;
– tinea pedis: 1 week 1 time per day;
– pityriasis versicolor: 1 week 1 time per day.
dosing regimen in the elderly does not require changes.
Before the first use must pierce sealing membrane tube by means of the tip on the outer side of the cap.
you must thoroughly clean and dry the affected area before applying the medication. Gel gently rubbed into the affected sites as well as the adjacent intact skin. In case of infections involving diaper rash (under the breasts, between the fingers, in the gluteal folds and inguinal) area of ​​application of the gel can be covered with gauze, especially at night.
Reducing the severity of clinical manifestations are usually noted in the first days of treatment.
In the case of irregular or premature treatment termination are at risk of recurrent infection. In the event that after 2 weeks of treatment shows no sign of improvement, should clarify the diagnosis.
Use drug only according to the application and in the doses indicated in the instructions for use. If necessary, please consult your physician before using the drug.
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist

Additional information

Weight0.100 kg
Manufacturer

DR.REDDIS

There are no reviews yet.

Add your review